×
Cronos Group EBITDA 2017-2025 | CRON
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Cronos Group ebitda from 2017 to 2025. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
View More
Cronos Group EBITDA 2017-2025 | CRON
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Cronos Group ebitda from 2017 to 2025. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
Related Stocks
Company Name
Market
Cap
Chugai Pharmaceutical (CHGCY)
$77B
Zoetis (ZTS)
$70.7B
Takeda Pharmaceutical (TAK)
$47.2B
Daiichi Sankyo, - (DSNKY)
$41.5B
BeOne Medicines - (ONC)
$27.8B
Sandoz Group AG (SDZNY)
$24.6B
Summit Therapeutics (SMMT)
$19.2B
Merck (MKKGY)
$17.3B
Shionogi (SGIOY)
$14.3B
United Therapeutics (UTHR)
$13.5B
Neurocrine Biosciences (NBIX)
$13.4B
Orion OYJ (ORINY)
$11.1B
IPSEN (IPSEY)
$10.3B
Stevanato Group S.p.A (STVN)
$7.9B
Corcept Therapeutics (CORT)
$7.6B
Madrigal Pharmaceuticals (MDGL)
$7B
Ionis Pharmaceuticals (IONS)
$6.7B
Grifols, S.A (GRFS)
$6.7B
Hikma Pharmaceuticals Plc (HKMPF)
$6.2B
Ono Pharmaceutical (OPHLF)
$5.1B
Soleno Therapeutics (SLNO)
$4B
Hypermarcas (HYPMY)
$3.2B
Crinetics Pharmaceuticals (CRNX)
$3B
Catalyst Pharmaceuticals (CPRX)
$2.7B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$2.6B
NewAmsterdam Pharma (NAMS)
$2.5B
Centessa Pharmaceuticals (CNTA)
$2B
BioCryst Pharmaceuticals (BCRX)
$1.9B
ARS Pharmaceuticals (SPRY)
$1.8B
Ocular Therapeutix (OCUL)
$1.8B